Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: reappraisal after the BRUISE study.

BACKGROUND: Management of patients treated with oral anticoagulation (OAC) requiring a cardiovascular implantable electronic device (CIED) surgery is a challenge that requires balancing the risk of bleeding complications with the risk of thromboembolic events. Recently the approach of performing these procedures while the patient remains with a therapeutic international normalized ratio has gained interest due to several publications showing its relative safety. OBJECTIVES: To evaluate the safety and effectiveness of continuous use of OAC compared with heparin bridging in the perioperative setting of CIED surgery using a meta-analysis. METHODS: A systematic review of PubMed/MEDLINE, Ovid, and Elsevier databases was performed. Eligible randomized controlled trials and cohort studies were included. The outcomes studied were risk of clinically significant bleeding and of thromboembolic events. Our analysis was restricted to OAC with vitamin K antagonists. RESULTS: Of 560 manuscripts initially considered relevant, seven were included in the meta-analysis, totaling 2,191 patients. Data are reported as odds ratios (ORs) with confidence interval (CI) of 95%. Maintenance of OAC was associated with a significantly lower risk of postoperative bleeding compared with heparin bridge (OR = 0.25, 95% CI 0.17-0.36, P < 0.00001). There was no difference noted in the risk of thromboembolic events between the two strategies (OR = 1.86, 95% CI 0.29-12.17, P = 0.57). CONCLUSIONS: Uninterrupted use of OAC in the perioperative of CIED surgery was associated with a reduced risk of bleeding. This strategy should be considered the preferred one in patients at moderate-to-high risk of thromboembolic events.

Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial.

OBJECTIVE: We tested the hypothesis that direct intramyocardial injection of bone marrow mononuclear cells in patients with non-ischemic dilated cardiomyopathy can improve left ventricular function and physical capacity. METHODS: Thirty non-ischemic dilated cardiomyopathy patients with left ventricular ejection fraction <35% were randomized at a 1:2 ratio into two groups, control and treated. The bone marrow mononuclear cells group received 1.06±108 bone marrow mononuclear cells through mini-thoracotomy. There was no intervention in the control group. Assessment was carried out through clinical evaluations as well as a 6-min walk test, nuclear magnectic resonance imaging and echocardiogram. RESULTS: The bone marrow mononuclear cells group showed a trend toward left ventricular ejection fraction improvement, with magnectic resonance imaging - at 3 months, showing an increase from 27.80±6.86% to 30.13±9.06% (P=0.08) and returning to baseline at 9 months (28.78%, P=0.77). Magnectic resonance imaging showed no changes in left ventricular ejection fraction during follow-up of the control group (28.00±4.32%, 27.42±7.41%, and 29.57±4.50%). Echocardiogram showed left ventricular ejection fraction improved in the bone marrow mononuclear cells group at 3 months, 25.09±3.98 to 30.94±9.16 (P=0.01), and one year, 30.07±7.25% (P=0.001). The control group showed no change (26.1±4.4 vs 26.5±4.7 and 30.2±7.39%, P=0.25 and 0.10, respectively). Bone marrow mononuclear cells group showed improvement in New York Heart Association functional class, from 3.40±0.50 to 2.41±0.79 (P=0.002); patients in the control group showed no change (3.37±0.51 to 2.71±0.95; P=0.17). Six-minute walk test improved in the bone marrow mononuclear cells group (348.00±93.51m at baseline to 370.41±91.56m at 12 months, P=0.66) and there was a non-significant decline in the control group (361.25±90.78m to 330.00±123.42m after 12 months, P=0.66). Group comparisons were non-significant. CONCLUSION: The trend of intragroup functional and subjective improvement was not confirmed when compared to the control group. Direct intramyocardial application of bone marrow mononuclear cells in non-ischemic dilated cardiomyopathy was not associated with significant changes in left ventricular function. Differences observed within the bone marrow mononuclear cells group could be due to placebo effect or low statistical power.

Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial / Ensaio clínico prospectivo randomizado sobre terapia com células mononucleares da medula óssea para cardiomiopatia dilatada idiopática: INTRACELL

Objective: We tested the hypothesis that direct intramyocardial injection of bone marrow mononuclear cells in patients with non-ischemic dilated cardiomyopathy can improve left ventricular function and physical capacity. Methods: Thirty non-ischemic dilated cardiomyopathy patients with left ventricular ejection fraction <35% were randomized at a 1:2 ratio into two groups, control and treated. The bone marrow mononuclear cells group received 1.06±108 bone marrow mononuclear cells through mini-thoracotomy. There was no intervention in the control group. Assessment was carried out through clinical evaluations as well as a 6-min walk test, nuclear magnectic resonance imaging and echocardiogram. Results: The bone marrow mononuclear cells group showed a trend toward left ventricular ejection fraction improvement, with magnectic resonance imaging - at 3 months, showing an increase from 27.80±6.86% to 30.13±9.06% (P=0.08) and returning to baseline at 9 months (28.78%, P=0.77). Magnectic resonance imaging showed no changes in left ventricular ejection fraction during follow-up of the control group (28.00±4.32%, 27.42±7.41%, and 29.57±4.50%). Echocardiogram showed left ventricular ejection fraction improved in the bone marrow mononuclear cells group at 3 months, 25.09±3.98 to 30.94±9.16 (P=0.01), and one year, 30.07±7.25% (P=0.001). The control group showed no change (26.1±4.4 vs 26.5±4.7 and 30.2±7.39%, P=0.25 and 0.10, respectively). Bone marrow mononuclear cells group showed improvement in New York Heart Association functional class, from 3.40±0.50 to 2.41±0.79 (P=0.002); patients in the control group showed no change (3.37±0.51 to 2.71±0.95; P=0.17). Six-minute walk test improved in the bone marrow mononuclear cells group (348.00±93.51m at baseline to 370.41±91.56m at 12 months, P=0.66) and there was a non-significant decline in the control group ...

Objetivo: Testamos a hipótese de que a injeção intramiocárdica direta de células mononucleares de medula óssea em pacientes portadores de cardiomiopatia dilatada não-isquêmica pode melhorar a função ventricular e a capacidade física. Métodos: Trinta pacientes com cardiomiopatia dilatada não isquêmica e fração de ejeção 35% foram randomizados na razão 1:2 em grupos controle e tratado. Grupo células mononucleares de medula óssea recebeu 1,06 ± 108 células mononucleares de medula óssea por mini-toracotomia. Grupo controle não recebeu intervenção. Avaliação foi feita clinicamente e por teste de caminhada 6 minutos (T6m), ressonância magnética e ecocardiogramas. Resultados: Grupo células mononucleares de medula óssea mostrou tendência de melhora da Fração de ejeção - ressonância magnética aos 3 meses, 27,80±6,86% para 30,13±9,06% (P=0,08), retornando ao basal aos 9 meses (28,78%, P=0,77). Grupo controle não apresentou variação (28,00±4,32%; 27,42±7,41% e 29,57±4,50%). Ecocardiogramas - fração de ejeção melhorou no grupo células mononucleares de medula óssea aos 3 meses: 25,09±3,98 para 30,94±9,16 (P=0,01) e aos 12 meses (30,07±7,25%, P=0,001), enquanto o controle não variou: 26,1±4,4 vs. 26,5±4,7 e 30,2±7,39%, P=0,25 e 0,10, respectivamente). Células mononucleares de medula óssea melhorou classe funcional New York Heart Association: 3,40±0.50 para 2,41±0,79 (P=0,002); controles não mudaram (3,37±0,51 para 2,71±0,95; P=0,17). T6m melhorou no grupo células mononucleares de medula óssea (348,00±93,51 m inicial para 370,41±91,56 m aos 12 m, P=0,66) e declinou sem significância no ...

High doses of vascular endothelial growth factor 165 safely, but transiently, improve myocardial perfusion in no-option ischemic disease.

UNLABELLED: Gene therapy can induce angiogenesis in ischemic tissues. The aim of this study was to assess safety, feasibility, and results, both clinical and on myocardial perfusion, of gene therapy in refractory angina. This was a phase I/II, prospective, temporal-controlled series, clinical trial. Thirteen patients were maintained for minimum 6 months under optimized clinical management, and then received intramyocardial injections of 2000 µg plasmid vascular endothelial growth factor 165 and were followed by single-photon emission computed tomography (SPECT), treadmill tests, Minnesota quality of life questionnaire (QOL), and New York Heart Association (NYHA) functional plus Canadian Cardiovascular Society (CCS) angina classifications. There were no deaths, early or late. During the optimized clinical treatment, we observed worsening of rest ischemia scores on SPECT (p<0.05). After treatment, there was a transitory increase in myocardial perfusion at the third-month SPECT under stress (pre-operative [pre-op] 18.38 ± 7.51 vs. 3 months 15.31 ± 7.30; p<0.01) and at the sixth month under rest (pre-op 13.23 ± 7.98 vs. 6 months: 16.92 ± 7.27; p<0.01). One year after, there were improvements in treadmill test steps (pre-op 2.46 ± 2.07 vs.12 months 4.15 ± 2.23; p<0.01) and oxygen consumption (pre-op 7.66 ± 4.47 vs.12 months 10.89 ± 4.65; p<0.05), QOL (pre-op 48.23 ± 18.35 vs.12 months 28.31 ± 18.14; p<0.01) scores, and CCS (pre-op 3 [3-3.5] vs.12 months 2 [1-2.5]; p<0.01) and NYHA (pre-op 3 [3-3] vs. 2 [2-2] vs. 12 months 2 [1-2]; p<0.01) classes. Gene therapy demonstrated to be feasible and safe in this advanced ischemic cardiomyopathy patient sample. There were improvements in clinical evaluation parameters, and a transitory increase in myocardial perfusion detectable by SPECT scintigraphy. CLINICAL TRIAL REGISTRATION: NCT00744315 http://clinicaltrials.gov/

Results of simplified single-patch repair for complete atrioventricular septal defect.

BACKGROUND: Since Wilcox's description of the simplified single-patch technique for atrioventricular septal defect (AVSD) repair in 1997, several studies have compared that technique with the two-patch technique. OBJECTIVE: To report the mid- and long-term results of the simplified single-patch technique for complete AVSD repair. METHODS: Retrospective study of 16 consecutive cases between January 2001 and December 2011. The patients' mean age was 18.31 ± 34.19 months (2 months - 11 years), and their mean weight, 7.80 ± 6.12 kg (3.77 - 25.0 kg). Six patients were males and 14 had Down syndrome. Mean follow-up duration was 54.97 ± 47.79 months. RESULTS: Mean cardiopulmonary bypass time was 74.63 ± 18.48 min (49 - 112 min), and mean aortic cross-clamp time, 46.44 ± 11.89 min (34 - 67 min). Two patients died during hospitalization (12.5%), both of cardiovascular causes. Three patients underwent reoperation due to left atrioventricular (AV) valve regurgitation, and two had third-degree VA block, requiring permanent pacemaker implantation. No patient had left ventricular outflow tract obstruction. The 14 surviving patients remain asymptomatic, ten of whom with mild left VA valve regurgitation (71.42%). CONCLUSION: The simplified single-patch technique for complete AVSD repair proved to be feasible, providing adequate correction of the defects and favorable clinical and echocardiographic outcome in the mean 57.97-month follow-up.

Resultados da correção simplificada com enxerto único no defeito septal atrioventricular completo / Results of simplified single-patch repair for complete atrioventricular septal defect

FUNDAMENTO: Desde que Wilcox, em 1997, descreveu uma forma simplificada de correção do Defeito Septal Atrioventricular (DSAV) com enxerto único, diversos estudos têm sido realizados comparando-a à técnica com duplo enxerto. OBJETIVO: Relatar os resultados em médio e longo prazos da correção de DSAV completo pela técnica simplificada de enxerto único. MÉTODOS: Estudo retrospectivo de 16 casos consecutivos arrolados entre janeiro de 2001 e dezembro de 2011. A idade média foi 18,31 ± 34,19 meses (2 meses - 11 anos) e o peso 7,80 ± 6,12 Kg (3,77 - 25,0 Kg); 6 pacientes eram do sexo masculino e 14 eram portadores de Síndrome de Down. O tempo de seguimento médio foi de 54,97 ± 47,79 meses. RESULTADOS: O tempo médio de circulação extracorpórea foi 74,63 ± 18,48 min (49 - 112 min) e o de pinçamento aórtico, de 46,44 ± 11,89 min (34 - 67 min). Foram observados dois óbitos hospitalares (12,5%), ambos por causa cardiovascular. Três pacientes foram reoperados por regurgitação da valva atrioventricular (VA) esquerda e dois apresentaram bloqueio atrioventricular (BAV) completo com necessidade de implante de marca-passo definitivo. Não houve nenhum caso de obstrução da via de saída do ventrículo esquerdo. Os 14 pacientes sobreviventes permanecem assintomáticos, 10 deles com insuficiência da valva VA esquerda leve (71,42%). CONCLUSÃO: A técnica simplificada com enxerto único para correção de DSAV completo mostrou-se factível, associada à correção adequada dos defeitos e à favorável evolução clínica e ecocardiográfica nos 57,97 meses de seguimento médio avaliados.

BACKGROUND: Since Wilcox's description of the simplified single-patch technique for atrioventricular septal defect (AVSD) repair in 1997, several studies have compared that technique with the two-patch technique. OBJECTIVE: To report the mid- and long-term results of the simplified single-patch technique for complete AVSD repair. METHODS: Retrospective study of 16 consecutive cases between January 2001 and December 2011. The patients' mean age was 18.31 ± 34.19 months (2 months - 11 years), and their mean weight, 7.80 ± 6.12 kg (3.77 - 25.0 kg). Six patients were males and 14 had Down syndrome. Mean follow-up duration was 54.97 ± 47.79 months. RESULTS: Mean cardiopulmonary bypass time was 74.63 ± 18.48 min (49 - 112 min), and mean aortic cross-clamp time, 46.44 ± 11.89 min (34 - 67 min). Two patients died during hospitalization (12.5%), both of cardiovascular causes. Three patients underwent reoperation due to left atrioventricular (AV) valve regurgitation, and two had third-degree VA block, requiring permanent pacemaker implantation. No patient had left ventricular outflow tract obstruction. The 14 surviving patients remain asymptomatic, ten of whom with mild left VA valve regurgitation (71.42%). CONCLUSION: The simplified single-patch technique for complete AVSD repair proved to be feasible, providing adequate correction of the defects and favorable clinical and echocardiographic outcome in the mean 57.97-month follow-up.

Randomized study of surgical isolation of the pulmonary veins for correction of permanent atrial fibrillation associated with mitral valve disease.

OBJECTIVE: Chronic permanent atrial fibrillation is often due to mitral valve disease. The Cox maze procedure is the gold standard for treating this arrhythmia. Simpler techniques and ablation methods should have their efficacy tested in clinical practice. Our objective was to evaluate the effectiveness of surgical pulmonary vein isolation as compared with the Cox maze procedure. METHODS: Sixty patients were randomly assigned to control group, modified maze group (Cox maze III), and surgical isolation of the pulmonary veins (SPVI) group from July 1999 to October 2004. All patients had mitral valve lesions treated concomitantly. Preoperative characteristics were similar between groups. RESULTS: There were 4 deaths: 3 in the Cox maze group and 1 in the SPVI group (P = .31). The Cox maze group presented longer times of extracorporeal circulation and myocardial ischemia (P < .001). The relative risk of late postoperative development of atrial fibrillation was 0.07 in the SPVI group (P < .001; 95% confidence intervals: 0.02-0.27) and 0.195 in the Cox maze group (P = .002; 95% confidence intervals: 0.07-0.56) as compared with the control group. No difference was found between the SPVI and Cox maze groups concerning prevention of atrial fibrillation recurrence (relative risk: 0.358; P = .215; 95% confidence intervals: 0.08-1.67). CONCLUSIONS: The modified Cox maze procedure and surgical pulmonary vein isolation were similarly effective in restoring sinus or regular rhythm in permanent atrial fibrillation associated with mitral valve disease. These results favor the adoption of surgical isolation as a preferable technique, simpler and equally effective in controlling atrial fibrillation. The results also can bring further information for understanding the mechanisms involved in origins and treatment of chronic permanent atrial fibrillation.

Unsupported valvuloplasty for degenerative mitral regurgitation: long-term results.

BACKGROUND: The advantages of valve repair for treatment of degenerative mitral regurgitation are well established. The procedure is associated with low mortality and morbidity rates, and low indices of reoperation, thromboembolic events and endocarditis have been reported. In most series, annuloplasty rings are implanted, but some institutions give preference to unsupported valvuloplasty. OBJECTIVE: To assess the clinical outcome of patients submitted to unsupported valvuloplasty for degenerative mitral regurgitation. METHODS: Between January 1980 and January 2003, 116 patients were submitted to the procedure. A total of 62 (53.4%) were men, and mean age was 47.2 +/- 16.5 years. The procedures included: Wooler annuloplasty (65.5%), unilateral annuloplasty (15.5%), quadrangular resection of the posterior leaflet (35.3%), anterior chordal shortening (20.7%), posterior chordal shortening (6.9%), and calcium debridement (0.9%). Mean follow-up was 6.5 +/- 5.1 years, and the longest follow-up was 24 years. RESULTS: Mortality was 0.86% (1 pt) early and 6.03% (7 pt) late. Actuarial survival was 85.3% in 20 years. Most patients (55.2%) presented preoperative NYHA functional class III, whereas class I was more frequent in the postoperative period (66.4%). Thromboembolic complications were observed in 4 patients (3.4%), and no correlation was seen with atrial fibrillation. Freedom from thromboembolic events was 94.8%, and similar results were observed for bacterial endocarditis. Survival free from reoperation was 79%, and 53% at 5 and 10 years, respectively. CONCLUSION: Unsupported valvuloplasty is effective and safe for treatment of degenerative mitral regurgitation, representing an adequate therapeutic alternative for selected cases.

Valvoplastia sem suporte para insuficiência mitral degenerativa: resultados a longo prazo / Unsupported valvuloplasty for degenerative mitral regurgitation: long-term results

FUNDAMENTO: As vantagens do reparo valvar para tratamento de insuficiência mitral degenerativa estão bem estabelecidas. O procedimento está associado com baixas taxas de morbimortalidade, e foram relatados baixos índices de reoperação, eventos tromboembólicos e endocardite. Na maior parte das séries, são implantados anéis para anuloplastia, mas algumas instituições preferem valvoplastia sem suporte. OBJETIVO: Avaliar a evolução clínica de pacientes submetidos à valvoplastia sem suporte para tratamento de insuficiência mitral degenerativa. MÉTODOS: Entre janeiro de 1980 e janeiro de 2003, 116 pacientes foram submetidos ao procedimento. Sessenta e dois (53,4 por cento) eram do sexo masculino, e a media de idade era 47,2 ± 16,5 anos. Os procedimentos empregados foram: Anuloplastia tipo Wooler (65,5 por cento), anuloplastia unilateral (15,5 por cento), ressecção quadrangular da cúspide posterior (35,3 por cento), encurtamento de corda tendínea anterior (20,7 por cento), encurtamento de corda tendínea posterior (6,9 por cento) e desbridamento do cálcio (0,9 por cento). O período médio de acompanhamento foi de 6,5 ± 5,1, e o acompanhamento mais longo foi de 24 anos. RESULTADOS: A mortalidade precoce foi de 0,86 por cento (1 paciente), e a mortalidade tardia foi de 6,03 por cento (7 pacientes). A sobrevida atuarial foi de 85,3 por cento em vinte anos. A maioria dos pacientes (55,2 por cento) apresentava classe funcional III no período pré-operatório, enquanto no período pós-operatório a classe funcional I foi mais freqüente (66,4 por cento). Quatro pacientes (3,4 por cento) tiveram complicações tromboembólicas, e não foi observada correlação com fibrilação atrial. A sobrevida livre de eventos tromboembólicos foi de 94,8 por cento, e resultados semelhantes foram observados para endocardite bacteriana. A sobrevida livre de reoperação foi de 79 por cento e 53 por cento aos 5 e 10 anos, respectivamente. CONCLUSÃO: Valvoplastia sem suporte é um procedimento...

BACKGROUND: The advantages of valve repair for treatment of degenerative mitral regurgitation are well established. The procedure is associated with low mortality and morbidity rates, and low indices of reoperation, thromboembolic events and endocarditis have been reported. In most series, annuloplasty rings are implanted, but some institutions give preference to unsupported valvuloplasty. OBJECTIVE: To assess the clinical outcome of patients submitted to unsupported valvuloplasty for degenerative mitral regurgitation. METHODS: Between January 1980 and January 2003, 116 patients were submitted to the procedure. A total of 62 (53.4 percent) were men, and mean age was 47.2 ± 16.5 years. The procedures included: Wooler annuloplasty (65.5 percent), unilateral annuloplasty (15.5 percent), quadrangular resection of the posterior leaflet (35.3 percent), anterior chordal shortening (20.7 percent), posterior chordal shortening (6.9 percent), and calcium debridement (0.9 percent). Mean follow-up was 6.5 ± 5.1 years, and the longest follow-up was 24 years. RESULTS: Mortality was 0.86 percent (1 pt) early and 6.03 percent (7 pt) late. Actuarial survival was 85.3 percent in 20 years. Most patients (55.2 percent) presented preoperative NYHA functional class III, whereas class I was more frequent in the postoperative period (66.4 percent). Thromboembolic complications were observed in 4 patients (3.4 percent), and no correlation was seen with atrial fibrillation. Freedom from thromboembolic events was 94.8 percent, and similar results were observed for bacterial endocarditis. Survival free from reoperation was 79 percent, and 53 percent at 5 and 10 years, respectively. CONCLUSION: Unsupported valvuloplasty is effective and safe for treatment of degenerative mitral regurgitation, representing an adequate therapeutic alternative for selected cases.

Hospital risk factors for bovine pericardial bioprosthesis valve implantation.

BACKGROUND: Identification of preoperative heart valve surgery risk factors aim to improve surgical outcomes with the possibility to offset conditions related to increased morbidity and mortality. OBJECTIVE: Intent of this study is to identify hospital risk factors in patients undergoing bovine pericardial bioprosthesis implantation. METHODS: Retrospective study including 703 consecutive patients who underwent implantation of at least one St. Jude Medical-Biocor bovine pericardial bioprosthesis between September 1991 and December 2005 at the Rio Grande do Sul Cardiology Institute; 392 were aortic, 250 were mitral and 61 were mitroaortic. Characteristics analyzed were gender, age, body mass index, NYHA (New York Heart Association) functional class, ejection fraction, valve lesions, systemic hypertension, diabetes mellitus, kidney function, arrhythmias, prior heart surgery, coronary artery bypass graft, tricuspid valve surgery and elective, urgent or emergency surgery. Main outcome was in-hospital mortality. Relationship between risk factors and in-hospital mortality was analyzed using logistic regression. RESULTS: Were 101 (14.3%) in-hospital deaths. Characteristics with significant relationship to increased mortality were female gender (p<0.001), age over 70 years (p=0.004), atrial fibrillation (p=0.006), diabetes mellitus (p=0.043), creatinine > 2.4 mg/dl (p=0.004), functional class IV (p<0.001), mitral valve lesion (p<0.001), previous heart surgery (p=0.005), tricuspid valve surgery (p<0.001) and emergency surgery (p<0.001). CONCLUSION: Mortality rate observed is accepted by literature and is justifiable due to the high prevalence of risk factors, showing an increased significance level for female gender, age above 70, functional class IV, tricuspid valve repairs and emergency surgery. Offsetting these factors could contribute to reduced in-hospital mortality for valve surgery.

Fatores de risco hospitalar para implante de bioprótese valvar de pericárdio bovino / Hospital risk factors for bovine pericardial bioprosthesis valve implantation

FUNDAMENTO: Identificação de fatores de risco pré-operatórios na cirurgia cardíaca valvar visa melhor resultado cirúrgico pela possível neutralização de condições relacionadas com morbi-mortalidade aumentada. OBJETIVO: Este estudo objetiva identificar fatores de risco hospitalar em pacientes submetidos a implante de bioprótese de pericárdio bovino. MÉTODOS: Estudo retrospectivo incluindo 703 pacientes consecutivos submetidos a implante de pelo menos uma bioprótese de pericárdio bovino St. Jude Medical-Biocor® de setembro de 1991 a dezembro de 2005 no Instituto de Cardiologia do RS, sendo 392 aórticos, 250 mitrais e 61 mitro-aórticos. Analisadas as características sexo, idade, índice de massa corporal, classe funcional (New York Heart Association - NYHA), fração de ejeção, lesão valvar, hipertensão arterial sistêmica, diabete melito, função renal, arritmias cardíacas, cirurgia cardíaca prévia, revascularização miocárdica, plastia tricúspide e caráter eletivo, de urgência ou de emergência da cirurgia. Desfecho primordial foi mortalidade hospitalar. Utilizou-se regressão logística para examinar relação entre fatores de risco e mortalidade hospitalar. RESULTADOS: Ocorreram 101 (14,3 por cento) óbitos hospitalares. Características significativamente relacionadas à mortalidade aumentada foram sexo feminino (p<0,001), idade superior a 70 anos (p=0,004), fibrilação atrial (p=0,006), diabete melito (p=0,043), creatinina > 2,4mg/dl (p=0,004), classe funcional IV (p<0,001), lesão valvar mitral (p<0,001), cirurgia cardíaca prévia (p=0,005), plastia tricúspide (p<0,001) e caráter cirúrgico emergencial (p<0,001). CONCLUSÃO: Observada mortalidade aceita pela literatura, justificável pela prevalência de alguns fatores de risco, tendo elevado nível de significância sexo feminino, idade superior a 70 anos, classe funcional IV, plastia tricúspide e caráter emergencial. A possível neutralização destes poderá contribuir para redução da mortalidade hospitalar...

BACKGROUND: Identification of preoperative heart valve surgery risk factors aim to improve surgical outcomes with the possibility to offset conditions related to increased morbidity and mortality. OBJECTIVE: Intent of this study is to identify hospital risk factors in patients undergoing bovine pericardial bioprosthesis implantation. METHODS: Retrospective study including 703 consecutive patients who underwent implantation of at least one St. Jude Medical-Biocor™ bovine pericardial bioprosthesis between September 1991 and December 2005 at the Rio Grande do Sul Cardiology Institute; 392 were aortic, 250 were mitral and 61 were mitroaortic. Characteristics analyzed were gender, age, body mass index, NYHA (New York Heart Association) functional class, ejection fraction, valve lesions, systemic hypertension, diabetes mellitus, kidney function, arrhythmias, prior heart surgery, coronary artery bypass graft, tricuspid valve surgery and elective, urgent or emergency surgery. Main outcome was in-hospital mortality. Relationship between risk factors and in-hospital mortality was analyzed using logistic regression. RESULTS: Were 101 (14.3 percent) in-hospital deaths. Characteristics with significant relationship to increased mortality were female gender (p<0.001), age over 70 years (p=0.004), atrial fibrillation (p=0.006), diabetes mellitus (p=0.043), creatinine > 2.4mg/dl (p=0.004), functional class IV (p<0.001), mitral valve lesion (p<0.001), previous heart surgery (p=0.005), tricuspid valve surgery (p<0.001) and emergency surgery (p<0.001). CONCLUSION: Mortality rate observed is accepted by literature and is justifiable due to the high prevalence of risk factors, showing an increased significance level for female gender, age above 70, functional class IV, tricuspid valve repairs and emergency surgery. Offsetting these factors could contribute to reduced in-hospital mortality for valve surgery.

The influence of time on the characteristics and risk factors for patients submitted to myocardial revascularization.

OBJECTIVE: To compare the clinical and surgical profile between two groups of patients submitted to Myocardial Revascularization (MCR) surgery at the Instituto de Cardiologia of Rio Grande do Sul with a ten year interval, to observe its influence upon MCR hospital mortality and to verify the predictability of this result using the risk score. METHODS: A retrospective cohort study involving 307 patients who underwent MCR surgery within a six month period during 1991/92 (INITIAL group, n=153) or 2001/02 (CURRENT group, n=154). Demographic characteristics, heart disease, comorbidities and surgical events were analyzed to compare the groups and to define the hospital mortality risk score (based on the Cleveland Clinic method). RESULTS: The CURRENT group was older, had more severe heart condition (functional class, incidence of heart failure and number of vessels with severe lesions) and a greater prevalence of comorbidities. The INITIAL group had a higher prevalence of nonelective surgery. Both groups had similar mean risk scores (2.8 +/- 3.1 for INITIAL and 2.2 +/- 2.5 for CURRENT) and hospital mortality rates (3.3% and 1.9% respectively). These figures are comparable to those for reported by Cleveland Clinic (for a risk score of 3 the predicted mortality range between 2.0 %; using a confidence level of 95% the predicted mortality is between 0 and 4.3%; and actual mortality confirmed by the study was 3.4%). CONCLUSION: Patients currently submitted to MCR are older and in worse clinical condition (heart and systemic) than those operated on ten years ago; however, the risk scores and hospital mortality rates were slightly higher in the INITIAL group. The higher number of nonelective surgical interventions could have contributed to this. A risk score can be used to identify patients that require a higher level of care and to predict surgical outcomes.

Aortic valve replacement with anterior and posterior enlargement of small aortic annulus is comparable to surgery with normal annulus.

OBJECTIVE: To compare results of aortic valve replacement in patients with normal annulus and in those undergoing anterior and posterior enlargement of a small annulus to implant a larger prosthesis. METHODS: The study included 22 patients with enlargement of a small aortic annulus and 23 with a normal aortic annulus, with similar demographic characteristics and selected from a large surgical population. For normal annulus, simple valve replacement was performed. For annular enlargement, the posterior approach required incision in the mid portion of the non-coronary sinus, up to the anterior mitral leaflet; anterior enlargement was achieved by an incision between the left and right coronary ostium, extended to the ventricular septum for 2 cm. The aorta was reconstructed with bovine pericardium patches. The results analyzed included diameter of aortic annulus at surgery, clinical evolution (2 to 11 years of follow-up), left outflow tract obstruction and left ventricular mass (by Doppler echocardiography). RESULTS: Enlargement increased the aortic annulus from 18.3 +/- 2.2 mm to 24.8 +/- 2.0 mm (p < 0.001), a value similar to aortic annulus considered normal: 24.9 +/- 1.5 mm (NS). For annular enlargement, the peak systolic gradient at the prosthesis decreased from 83.6 +/- 22.3 mmHg (preoperative) to 26.7 +/- 11.4 mmHg (p < 0.01) at the last evaluation. For normal annulus, a reduction from 68.2 +/- 28.7 mmHg to 32.8 +/- 16.2 mmHg occurred (p < 0.001) (final values similar between groups; NS). Left ventricular mass at the last evaluation was 147.2 +/- 45.9 for patients with enlargement and 148.1 +/- 70.4 for those with normal annulus. CONCLUSION: Anterior and posterior aortic annulus enlargement enabled increases in annular diameter and valve prosthesis size, providing clinical and echocardiographic results similar to patients with valve replacement in a normal annulus.

Influências temporais nas características e fatores de risco de pacientes submetidos a revascularização miocárdica / The influence of time on the characteristics and risk factors for patients submitted to myocardial revascularization / The influence of time on the characteristics and risk factors for patients submitted to myocardial revascularization

OBJETIVO: Comparar perfil clínico e cirúrgico entre dois grupos de pacientes submetidos a Cirurgia de Revascularização Miocárdica (CRM) no Instituto de Cardiologia do Rio Grande do Sul, com intervalo de 10 anos; observar sua influência na mortalidade hospitalar e verificar previsibilidade deste resultado mediante escore de risco. MÉTODOS: Estudo de coorte retrospectivo, envolvendo 307 pacientes submetidos a CRM isolada em período semestral de 1991/92 (grupo INICIAL, n=153) ou 2001/02 (grupo ATUAL, n=154). Foram analisados características demográficas, doenças cardíacas, co-morbidades e eventos operatórios, visando à comparação entre grupos e definição do escore de risco de morte hospitalar (conforme Cleveland Clinic). RESULTADOS: O grupo ATUAL tinha idade mais avançada, condição cardíaca mais grave (classe funcional, prevalência de insuficiência cardíaca e número de vasos com lesão severa) e maior prevalência de co-morbidades. Os pacientes iniciais mostraram maior prevalência na indicação cirúrgica de urgência. Não ocorreu diferença no escore médio de risco calculado para ambos os grupos (2,8 + 3,1 no INICIAL e 2,2 + 2,5 no ATUAL) ou na mortalidade hospitalar (respectivamente 3,3 por cento e 1,9 por cento), valores comparáveis com os comunicados pela Cleveland Clinic (para escore de risco 3, mortalidade prevista de 2,0 por cento, com limite de confiança 95 por cento de 0-4,3 por cento e mortalidade real em estudo de confirmação de 3,4 por cento). CONCLUSÃO: Pacientes atualmente submetidos a CRM são mais idosos e em pior condição clínica (cardíaca e sistêmica) que os operados há 10 anos, mas a pontuação no escore de risco e a mortalidade hospitalar foram discretamente aumentadas no grupo inicial. Para isto, pode ter contribuído maior prevalência de cirurgias de urgência. Um escore de risco pode ser utilizado para identificar pacientes que requerem maiores cuidados e predizer o resultado cirúrgico.

OBJECTIVE: To compare clinical and surgical and clinical profiles of two group of patients submitted to Coronary Artery Bypass Graft (CABG) at Instituto de Cardiologia do RGS within a decade interval, define related hospital mortality and to validate a severity risk score for this populations. METHODS: Retrospective cohort study, including 307 CABG patients operated during six months of 1991/92 (n=153) and 2001/02 (n=154). Demographic characteristics, heart disease severity, co-morbidities and pre-operative events were evaluated and compared between groups. Hospital mortality and severity risk scores for mortality according to Cleveland Clinic were also assessed. RESULTS: Patients operated in 2001/02 were older, had more severe cardiac disease (increased NYHA functional class, prevalence of heart failure, and distribution of coronary diseased) and presented more co-morbidities than those operated in 1991/92. This patients required urgent surgery more often. The mean Cleveland Clinic severity risk score wasn't different between groups (2.8 + 3.1 in 1991/92 and 2.2 + 2.5 in 2001/02) and hospital mortality didn't present significant difference (3.3 percent and 1.9 percent, respectively). For Cleveland Clinic score 3 the predicted mortality was estimated as 2.0 percent (with confidence limit 95 percent of 0- 4.3 percent) and observed mortality for surgical patients of this institution was 3.4 percent. CONCLUSION: Patients submitted to CABG currently are older and in worse clinical conditions than those operated 10 years ago, but severity risk scores and hospital mortality were discretely increased for initial series of patients. This may be a consequent of a higher prevalence of urgent surgical indication in those patients. A severity risk score for hospital mortality can be used to predict surgical result and identify patients requiring specific care.

Bioprótese valvar de pericárdio bovino St Jude Medical-Biocor: sobrevida tardia / St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival

OBJETIVO: Nosso objetivo é apresentar resultados a longo prazo da subsituicão valvar por bioprótese de pericárdio bovino SJM-BiocorTM. MÉTODO: Entre 1992 e 2000, tiveram alta hospitalar, após substituicão valvar por bioprótese de pericárdio bovino SJM-BiocorTM 304 pacientes. Idades eram de 15 a 83 anos (média: 60,6n14,3), sendo 50,3 por cento do sexo masculino. Pacientes tiveram situacão clínica atualizada e análise atuarial foi empregada no cálculo da sobrevida simples e livre de eventos. RESULTADOS: Em um seguimento total de 931,0 pacientes-ano, ocorreram 28 (9,2 por cento) óbitos tardios, sendo cinco (1,6 por cento) relacionados à bioprótese, sete (2,3 por cento) cardíacos, quatro (1,3 por cento) não-cardíacos e 12 (3,9 por cento) de causa desconhecida. Eventos de bioprótese foram: endocardite: 18 (5,9 por cento), degeneracão fibrocálcica: 15 (4,9 por cento), tromboembolismo: três (1,0 por cento), hemólise: um (0,3 por cento). Disfuncão de bioprótese resultou em 16 (5,2 por cento) reoperacões, por degeneracão fibrocálcica (nove), endocardite (seis) e tromboembolismo (um). Probabilidade de sobrevida foi 86,3n3,4 por cento, no 5º, e 69,3n9,0 por cento, no 10º ano pós-operatório. Idade jovem (<40 anos, n= 35) mostrou maior sobrevida em relacão à mais idosa (>60 anos, n=187): 82,0n13,3 por cento vs 58,8n13,6 por cento, no 9º ano. Sobrevida livre de eventos foi 77,5n3,7 por cento, no 5º, e 40,2n9,0 por cento, no 10º ano. Probabilidade de falência estrutural de bioprótese foi 5 por cento, no 5º ano, e 20 por cento, no 10º; em aórticos, zero e 8 por cento, respectivamente. A classe funcional (NYHA) atual é I para 88,5 por cento, II para 9,1 por cento e III para 2,4 por cento dos pacientes. CONCLUSAO: Implante de bioprótese de pericárdio bovino SJM-BiocorTM resulta em satisfatória perspectiva de sobrevida dos pacientes com doenca valvar e apresenta baixa prevalência de disfuncão de prótese.

Modificacões no perfil do paciente submetido à operacão de revascularizacão do miocárdio / Changes in profile of patients submitted to coronary bypass graft surgery

INTRODUÇAO: Indicacões da operacão de revascularizacão miocárdica (RM) foram modificadas pela introducão de novas drogas e da angioplastia coronária transluminal percutânea (ACTP), sendo o procedimento cada vez considerado em pacientes com doenca multiarterial coronária e de condicão clínica mais grave. OBJETIVO: Comparar perfil clínico e cirúrgico entre dois grupos de pacientes submetidos a RM com intervalo de 10 anos, bem como observar sua influência na mortalidade hospitalar. MÉTODO: Estudo de coorte retrospectivo, envolvendo 307 pacientes submetidos a RM em 1991/92 (grupo INICIAL, n=153) ou 2001/02 (grupo ATUAL, n=154). Para cada grupo foram identificadas características demográficas, doencas cardíacas, co-morbidades e eventos operatórios, visando comparacão e determinacão dos fatores relacionados à mortalidade hospitalar aumentada. RESULTADOS: Grupo recente tinha idade mais avancada, condicão cardíaca mais grave(classe funcional, prevalência de insuficiência cardíaca e número de vasos com lesão grave) e maior prevalência de co-morbidades. Pacientes iniciais mostraram maior prevalência na indicacão cirúrgica de urgência. Não ocorreu diferenca na mortalidade hospitalar (respectivamente 3,3 por cento e 1,9 por cento para grupos INICIAL e ATUAL). CONCLUSÕES: Pacientes atualmente submetidos a RM são mais idosos e de condicão clínica mais grave (cardíaca e sistêmica) que os operados há 10 anos, embora isto não tenha influenciado de modo significativo a mortalidade hospitalar, que é menor recentemente.

Resultado da substituição aórtica por ampliação anelar anterior e posterior é comparável a do anel normal / Similar results of valve replacement with normal aortic annulus or anterior and posterior annular enlargement

OBJETIVO: Comparar resultados tardios da substituição valvar no anel aórtico com ou sem ampliação. MÉTODO: Incluídos 22 pacientes aórticos com ampliação anelar anterior e posterior por anel pequeno e 23 com diâmetro anelar normal quando da substituição valvar aórtica. Para grupos, foram comparáveis características como sexo, idade, diagnóstico valvar, etiologia da doença e lesões associadas. Substituição valvar simples foi rotineira. Para ampliação anelar posterior foi feita incisão no ponto médio do seio não coronariano, estendida ao folheto mitral anterior; ampliação anterior resultou de incisão no anel aórtico anterior, estendida por 2 cm no septo interventricular, não transfixado; reconstrução aórtica foi realizada por enxertos de pericárdio bovino. Resultados considerados para toda amostra foram características operatórias, evolução clínica (seguimento de 2 a 11 anos) e gradiente na via de saída do ventrículo esquerdo (VSVE) ao ecocardiograma Doppler. RESULTADOS: Ampliação aumentou diâmetro anelar aórtico de 18,3±2,2 mm para 24,8±2,0 mm (p<0,001), tornando-o comparável ao normal: 24,9±1,5 mm (NS). Foi necessário maior tempo de circulação extracorpórea para ampliação anelar (122,1±38,9 min vs 91,0±30,7 min; p<0,005) e de pinçamento aórtico (91,6±20,7 min vs 68,0±23,5 min; p<0,001). Para ampliação anelar, o gradiente sistólico máximo na VSVE reduziu de 83,6±22,3 mmHg no pré-operatório para 26,7±11,4 mmHg (p<0,01), recentemente, e na substituição valvar simples a redução foi de 68,2±28,7 mmHg para 32,8±16,2 mmHg (P<0,001); valores comparáveis para intervalos correspondentes (NS). CONCLUSAO: Técnica de ampliação anterior e posterior do anel aórtico possibilitou aumento do diâmetro anelar e do substituto protético implantado, sendo que para até 11 anos de seguimento o resultado clínico e ecocardiográfico foi superponível ao da substituição aórtica em pacientes com anel normal.

Estudo randomizado de correção cirúrgica de fibrilação atrial permanente: resultados parciais / Randomized study of surgical correction of permanent atrial fibrillation: preliminary results

OBJETIVO: Analisar os resultados de dois modos de tratar a fibrilação atrial (FA): com cirurgia do Labirinto e com Isolamento de Veias Pulmonares (IVP), comparando com grupo controle, para estabelecer o melhor tratamento aos portadores desta arritmia. MÉTODO:Todos os pacientes tinham indicação cirúrgica por outra lesão cardíaca, concomitantemente tratada. Foram randomizados 51 pacientes no período de julho de 1999 a setembro de 2003. Em nenhum paciente foi utilizada crioablação. Analisamos inicialmente as seguintes variáveis: tempo de circulação extracorpórea (CEC), pinçamento aórtico (ISQ), taxa de reversão a ritmo sinusal na alta hospitalar, e complicações do trans e pós-operatório imediato. RESULTADOS: Houve dois óbitos intra-hospitalares, um no grupo Labirinto e um no grupo IVP. O grupo Labirinto apresentou o maior tempo de CEC (p<0,001). Seguimento médio de 28,4 mais ou menos 14,1 meses, sem diferença entre os grupos. O grupo IVP teve a maior taxa de sucesso com 84,2 por cento de reversão a ritmo sinusal na alta e 88,9 por cento após seguimento. No grupo Labirinto, 78,5 por cento de ritmo sinusal à alta, e após seguimento, 84,6 por cento. No grupo controle, 87,5 por cento dos pacientes tiveram alta em FA, e após seguimento 56,3 por cento seguem assim. A classe funcional pela NYHA não foi diferente entre os grupos após o seguimento (p=0,56), e os pacientes do grupo controle apresentaram mais complicações (p=0,017). CONCLUSAO: Estes resultados mostram que qualquer das técnicas empregadas para correção de FA, Labirinto ou IVP, apresenta vantagens sobre a operação tradicional de simples correção de cardiopatias quando associadas à FA.

Emprego de sistemas robóticos na cirurgia cardiovascular / Robotic systems in cardiovascular surgery

O desenvolvimento de sistemas robóticos para cirurgia teve início na década de 80, por solicitação do exército norte-americano, que antevia a possibilidade de realizar operações em teatros de guerra, distantes do local onde estava o cirurgião. Entretanto, o primeiro uso em humanos só ocorreu anos mais tarde, numa ressecção transuretral de hiperplasia benigna de próstata. Cirurgiões cardíacos foram logo atraídos pela técnica robótica devido a possível aplicação com reduzido caráter invasivo; esperava-se menor trauma cirúrgico e redução da dor, morbidade, tempo de internação e custo do procedimento. Atualmente, de forma restrita e em casos selecionados, robôs são usados para revascularização do miocárdio e implante de marcapasso em cirurgias cardíacas totalmente endoscópicas; podendo também constituir apoio visual na retirada de artéria torácica interna, reconstrução valvar mitral e correção de defeitos congênitos. Utilizando o robô auxiliar AESOP® para controle do videotoracoscópio, com controle vocal por meio do sistema HERMES®, temos realizado dissecção da artéria torácica interna, implante de eletrodo ventricular esquerdo e abordagem de defeitos congênitos na cirurgia de correção. Apesar do entusiasmo científico inicial com a cirurgia robótica, ainda não existe evidência clara de superioridade desta técnica em relação à operação convencional, em termos de resultado. Isto se aplica também ao custo, pois o investimento inicial na aquisição de sistema cirúrgico completo (console, controle de vídeo, instrumental) provavelmente é compensado após muitos procedimentos e longo intervalo. Mas é certo que a cirurgia robótica terá um lugar no futuro, possibilitando aprendizagem, telepresença e realização de procedimentos pouco invasivos, embora complexos.

Computer dynamics to evaluate blood flow through the modified Blalock-Taussig shunt

OBJETIVO: Dinâmica computacional foi utilizada para avaliar a influência de fatores geométricos no funcionamento de modelo da cirurgia de Blalock-Taussig modificada (BTm), ou interposiçäo de enxerto de politetrafluoretileno (PTFE) entre as artérias subclávia e pulmonar.